-
1
-
-
85055021376
-
Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
-
Dorsey ER. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53.
-
(2018)
Lancet Neurol
, vol.17
, Issue.11
, pp. 939-953
-
-
Dorsey, E.R.1
-
2
-
-
84941793151
-
precompetitive data sharing as a catalyst to address unmet needs in Parkinson’s disease
-
PID: 26406139
-
Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, et al. precompetitive data sharing as a catalyst to address unmet needs in Parkinson’s disease. J Parkinsons Dis. 2015;5(3):581–94.
-
(2015)
J Parkinsons Dis
, vol.5
, Issue.3
, pp. 581-594
-
-
Stephenson, D.1
Hu, M.T.2
Romero, K.3
Breen, K.4
Burn, D.5
Ben-Shlomo, Y.6
-
3
-
-
85046011853
-
Targeted therapies for Parkinson’s disease: from genetics to the clinic
-
Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson’s disease: from genetics to the clinic. Mov Dis. 2018;33(5):684–96.
-
(2018)
Mov Dis
, vol.33
, Issue.5
, pp. 684-696
-
-
Sardi, S.P.1
Cedarbaum, J.M.2
Brundin, P.3
-
4
-
-
78751688048
-
Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership
-
PID: 21041580
-
Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600–6.
-
(2010)
Ann Intern Med
, vol.153
, Issue.9
, pp. 600-606
-
-
Stang, P.E.1
Ryan, P.B.2
Racoosin, J.A.3
Overhage, J.M.4
Hartzema, A.G.5
Reich, C.6
-
5
-
-
84952053307
-
Observational health data sciences and informatics (OHDSI): opportunities for observational researchers
-
PID: 26262116
-
Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574–8.
-
(2015)
Stud Health Technol Inform
, vol.216
, pp. 574-578
-
-
Hripcsak, G.1
Duke, J.D.2
Shah, N.H.3
Reich, C.G.4
Huser, V.5
Schuemie, M.J.6
-
6
-
-
85029541597
-
β2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease
-
COI: 1:CAS:528:DC%2BC2sXhtl2kurrP, PID: 28860381
-
Mittal S, Bjornevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. β2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891–8.
-
(2017)
Science
, vol.357
, Issue.6354
, pp. 891-898
-
-
Mittal, S.1
Bjornevik, K.2
Im, D.S.3
Flierl, A.4
Dong, X.5
Locascio, J.J.6
-
7
-
-
85050009917
-
Network-based approach to prediction and population-based validation of in silico drug repurposing
-
PID: 30002366
-
Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabasi AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):2691.
-
(2018)
Nat Commun
, vol.9
, Issue.1
, pp. 2691
-
-
Cheng, F.1
Desai, R.J.2
Handy, D.E.3
Wang, R.4
Schneeweiss, S.5
Barabasi, A.L.6
-
8
-
-
84892945980
-
Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system
-
PID: 24166227
-
Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S95–106.
-
(2013)
Drug Saf
, vol.36
, pp. S95-S106
-
-
Ryan, P.B.1
Schuemie, M.J.2
Madigan, D.3
-
9
-
-
84892948635
-
A comparison of the empirical performance of methods for a risk identification system
-
PID: 24166231
-
Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143–58.
-
(2013)
Drug Saf
, vol.36
, pp. S143-S158
-
-
Ryan, P.B.1
Stang, P.E.2
Overhage, J.M.3
Suchard, M.A.4
Hartzema, A.G.5
DuMouchel, W.6
-
10
-
-
84892916187
-
Evaluating performance of risk identification methods through a large-scale simulation of observational data
-
PID: 24166233
-
Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013;36(Suppl 1):S171–80.
-
(2013)
Drug Saf
, vol.36
, pp. S171-S180
-
-
Ryan, P.B.1
Schuemie, M.J.2
-
11
-
-
84892947582
-
Empirical performance of the case-control method: lessons for developing a risk identification and analysis system
-
PID: 24166225
-
Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S73–82.
-
(2013)
Drug Saf
, vol.36
, pp. S73-S82
-
-
Madigan, D.1
Schuemie, M.J.2
Ryan, P.B.3
-
12
-
-
84908292293
-
A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends
-
PID: 25323155
-
Butt DA, Tu K, Young J, Green D, Wang M, Ivers N, et al. A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends. Neuroepidemiology. 2014;43(1):28–37.
-
(2014)
Neuroepidemiology
, vol.43
, Issue.1
, pp. 28-37
-
-
Butt, D.A.1
Tu, K.2
Young, J.3
Green, D.4
Wang, M.5
Ivers, N.6
-
13
-
-
0041876133
-
Measuring inconsistency in meta-analyses
-
PID: 192859
-
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
-
(2003)
BMJ
, vol.327
, Issue.7414
, pp. 557-560
-
-
Higgins, J.P.1
Thompson, S.G.2
Deeks, J.J.3
Altman, D.G.4
-
14
-
-
79955544813
-
Interpretation of random effects meta-analyses
-
PID: 21310794
-
Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
-
(2011)
BMJ
, vol.342
, pp. d549
-
-
Riley, R.D.1
Higgins, J.P.T.2
Deeks, J.J.3
-
15
-
-
84881589353
-
Evaluating the impact of database heterogeneity on observational study results
-
PID: 23648805
-
Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645–51.
-
(2013)
Am J Epidemiol
, vol.178
, Issue.4
, pp. 645-651
-
-
Madigan, D.1
Ryan, P.B.2
Schuemie, M.3
Stang, P.E.4
Overhage, J.M.5
Hartzema, A.G.6
-
16
-
-
85055879668
-
β2-adrenoreceptor medications and risk of Parkinson disease
-
COI: 1:CAS:528:DC%2BC1cXitlGgsbjE, PID: 30225948
-
Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA. β2-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018;84(5):683–93.
-
(2018)
Ann Neurol
, vol.84
, Issue.5
, pp. 683-693
-
-
Searles Nielsen, S.1
Gross, A.2
Camacho-Soto, A.3
Willis, A.W.4
Racette, B.A.5
-
17
-
-
84940392979
-
Feasibility and utility of applications of the common data model to multiple, disparate observational health databases
-
PID: 25670757
-
Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553–64.
-
(2015)
J Am Med Inform Assoc
, vol.22
, Issue.3
, pp. 553-564
-
-
Voss, E.A.1
Makadia, R.2
Matcho, A.3
Ma, Q.4
Knoll, C.5
Schuemie, M.6
-
18
-
-
85021636304
-
Nicotine from cigarette smoking and diet and Parkinson disease: a review
-
PID: 28680589
-
Ma C, Liu Y, Neumann S, Gao X. Nicotine from cigarette smoking and diet and Parkinson disease: a review. Transl Neurodegener. 2017;6:18.
-
(2017)
Transl Neurodegener
, vol.6
, pp. 18
-
-
Ma, C.1
Liu, Y.2
Neumann, S.3
Gao, X.4
-
20
-
-
77953185520
-
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors
-
COI: 1:CAS:528:DC%2BC3cXpsFGjtrw%3D, PID: 20590599
-
Baker JG. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010;160(5):1048–61.
-
(2010)
Br J Pharmacol
, vol.160
, Issue.5
, pp. 1048-1061
-
-
Baker, J.G.1
-
21
-
-
1442349847
-
Comparative pharmacology of human beta-adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells
-
COI: 1:CAS:528:DC%2BD2cXhtVygtbc%3D, PID: 14730417
-
Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(2):151–9.
-
(2004)
Naunyn Schmiedebergs Arch Pharmacol
, vol.369
, Issue.2
, pp. 151-159
-
-
Hoffmann, C.1
Leitz, M.R.2
Oberdorf-Maass, S.3
Lohse, M.J.4
Klotz, K.N.5
-
22
-
-
84891699606
-
Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis
-
PID: 24312590
-
Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013;8(12):e81802.
-
(2013)
PLoS One
, vol.8
, Issue.12
-
-
Sheng, P.1
Hou, L.2
Wang, X.3
Wang, X.4
Huang, C.5
Yu, M.6
-
23
-
-
84951951974
-
Catecholaminergic based therapies for functional recovery after TBI
-
COI: 1:CAS:528:DC%2BC2MXitVyqs77F, PID: 26711850
-
Osier ND, Dixon CE. Catecholaminergic based therapies for functional recovery after TBI. Brain Res. 2016;1640(Pt A):15–35.
-
(2016)
Brain Res
, vol.1640
, pp. 15-35
-
-
Osier, N.D.1
Dixon, C.E.2
-
24
-
-
84885368200
-
Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions
-
Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;7(4):139.
-
(2013)
Front Neurol
, vol.7
, Issue.4
, pp. 139
-
-
Wisor, J.1
-
25
-
-
85024403534
-
Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice
-
PID: 28521299
-
Wang QM, Xu YY, Liu S, Ma ZG. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. Oncotarget. 2017;8(29):47284–95.
-
(2017)
Oncotarget
, vol.8
, Issue.29
, pp. 47284-47295
-
-
Wang, Q.M.1
Xu, Y.Y.2
Liu, S.3
Ma, Z.G.4
-
26
-
-
85074541588
-
A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): baseline characteristics and study update [abstract no. P2.039]
-
Simuni T, Holloway R, Oakes D, Biglan K, Lungu C. A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): baseline characteristics and study update [abstract no. P2.039]. Neurology. 2018;90(15 Suppl):P2.39.
-
(2018)
Neurology
, vol.90
, pp. P2.39
-
-
Simuni, T.1
Holloway, R.2
Oakes, D.3
Biglan, K.4
Lungu, C.5
|